PMID- 20126479
OWN - NLM
STAT- MEDLINE
DCOM- 20100510
LR  - 20220409
IS  - 1545-6110 (Electronic)
IS  - 0065-9533 (Print)
IS  - 0065-9533 (Linking)
VI  - 107
DP  - 2009 Dec
TI  - Spectral-domain optical coherence tomography and adaptive optics may detect 
      hydroxychloroquine retinal toxicity before symptomatic vision loss.
PG  - 28-33
AB  - PURPOSE: To describe spectral-domain optical coherence tomography (SD-OCT) and 
      adaptive optics (AO) imaging in hydroxychloroquine retinal toxicity. METHODS: Two 
      patients with long-term hydroxychloroquine use, subtle perifoveal ophthalmoscopic 
      pigmentary changes, and bilateral perifoveal defects on automated Humphrey visual 
      field (HVF) 10-2 perimetry were imaged using SD-OCT and AO. RESULTS: SD-OCT 
      images demonstrated loss of photoreceptor inner segment/outer segment (IS/OS) 
      junction and a downward "sink-hole" displacement of inner retinal structures in 
      areas of hydroxychloroquine toxicity corresponding to HVF 10-2 defects and 
      ophthalmoscopic clinical examination findings. SD-OCT irregularities in the IS/OS 
      junction were also seen in areas not detected on HVF 10-2. AO images showed 
      disruption of the cone photoreceptor mosaic in areas corresponding to HVF 10-2 
      defects and SD-OCT IS/OS junction abnormalities. Additionally, irregularities in 
      the cone photoreceptor density and mosaic were seen in areas with normal HVF 10-2 
      and SD-OCT findings. CONCLUSIONS: SD-OCT and AO detected abnormalities that 
      correlate topographically with visual field loss from hydroxychloroquine toxicity 
      as demonstrated by HVF 10-2 and may be useful in the detection of subclinical 
      abnormalities that precede symptoms or objective visual field loss.
FAU - Stepien, Kimberly E
AU  - Stepien KE
AD  - Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, USA.
FAU - Han, Dennis P
AU  - Han DP
FAU - Schell, Jonathan
AU  - Schell J
FAU - Godara, Pooja
AU  - Godara P
FAU - Rha, Jungtae
AU  - Rha J
FAU - Carroll, Joseph
AU  - Carroll J
LA  - eng
GR  - EY001931/EY/NEI NIH HHS/United States
GR  - EY017607/EY/NEI NIH HHS/United States
GR  - R01 EY017607/EY/NEI NIH HHS/United States
GR  - R01 EY017607-03/EY/NEI NIH HHS/United States
GR  - P30 EY001931/EY/NEI NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Trans Am Ophthalmol Soc
JT  - Transactions of the American Ophthalmological Society
JID - 7506106
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Retinal Pigments)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Antirheumatic Agents/*adverse effects/therapeutic use
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Hydroxychloroquine/*adverse effects/therapeutic use
MH  - Lupus Erythematosus, Systemic/drug therapy
MH  - Middle Aged
MH  - Ophthalmoscopy
MH  - Optics and Photonics/*methods
MH  - Retina/drug effects/pathology
MH  - Retinal Cone Photoreceptor Cells/pathology
MH  - Retinal Diseases/*chemically induced/complications/*diagnosis/metabolism
MH  - Retinal Pigments/metabolism
MH  - Sjogren's Syndrome/drug therapy
MH  - Tomography, Optical Coherence/*methods
MH  - Vision Disorders/*etiology
MH  - Visual Field Tests
MH  - Visual Fields
PMC - PMC2814561
EDAT- 2010/02/04 06:00
MHDA- 2010/05/11 06:00
PMCR- 2009/12/01
CRDT- 2010/02/04 06:00
PHST- 2010/02/04 06:00 [entrez]
PHST- 2010/02/04 06:00 [pubmed]
PHST- 2010/05/11 06:00 [medline]
PHST- 2009/12/01 00:00 [pmc-release]
AID - 1545-6110_v107_p028 [pii]
PST - ppublish
SO  - Trans Am Ophthalmol Soc. 2009 Dec;107:28-33.